Revolutionizing Biotech Innovation through Cutting-Edge Partnerships
Geistek Pharmaceuticals is dedicated to supporting the vibrant biotech industry in its quest to bring groundbreaking therapies to patients in need. As a leading global CRO, we understand the unique challenges faced by biotech companies with limited resources and specialized focus. Our tailored approach and team of over 8,000 biotech-focused professionals ensure that we are aligned with your goals and equipped to deliver efficient and successful clinical trials.
With Geistek Pharmaceuticals, you gain access to a flexible partnership model that provides end-to-end integrated services. Our experienced team offers tailored clinical development solutions, leveraging streamlined processes and a single point of contact for accountability. We are committed to faster execution, certainty of cost, and senior management involvement to drive your project forward.
Geistek Pharmaceuticals goes beyond trial execution by offering robust consulting and advisory services. We provide strategic guidance on asset development, funding, regulatory compliance, and commercial positioning to maximize the value of your product. Our expertise spans various therapeutic areas, including novel therapies like Cell and Gene therapies and first-in-class immunotherapies.
Geistek Pharmaceuticals is proud to have the world's largest operational organization dedicated to working with small and mid-sized biopharma companies. Our dedicated resources understand the specific needs of biotechs and are committed to your study's success. With a biotech mindset, we prioritize your study from recruitment and training to development, ensuring the best possible outcomes.
Our empowered and aligned structure sets us apart, with industry-tenured Directors of Project Delivery overseeing every study and VP/General Partners providing governance and executive advocacy. With a direct connection to our CEO, we make quick decisions and adapt as needed, providing all the resources you require while keeping engagement simple.
Geistek Pharmaceuticals is focused on building enduring partnerships with biotech innovators to advance medicine and improve patient outcomes. As a trusted and reliable CRO, we offer a comprehensive suite of services tailored to your unique needs, leveraging our depth and breadth of experienced resources. Together, we will achieve your development milestones and deliver data-driven results that inspire confidence in investors, large pharma partners, regulatory authorities, and all stakeholders involved
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
